PriceTargets.com logo

Vericel - VCEL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $36.20
  • Forecasted Upside: 26.88%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$28.53 As of 01/27/2023 01:00 AM ET
▲ +0.68 (2.44%)

This chart shows the closing price for VCEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vericel Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VCEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VCEL

Analyst Price Target is $36.20
▲ +26.88% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vericel in the last 3 months. The average price target is $36.20, with a high forecast of $45.00 and a low forecast of $25.00. The average price target represents a 26.88% upside from the last price of $28.53.

This chart shows the closing price for VCEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Vericel. This rating has held steady since October 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/27/2023HC WainwrightReiterated RatingBuy$37.00Low
1/3/2023HC WainwrightBoost TargetBuy$35.00 ➝ $37.00Low
12/20/2022Truist FinancialBoost TargetHold$22.00 ➝ $25.00Low
11/15/2022Truist FinancialDowngradeHoldLow
11/10/2022HC WainwrightLower TargetBuy$53.00 ➝ $35.00Low
11/9/2022BTIG ResearchDowngradeBuy ➝ NeutralLow
11/9/2022Truist FinancialDowngradeBuy ➝ HoldLow
10/13/2022StephensInitiated CoverageOverweight$40.00Low
7/22/2022Truist FinancialLower Target$33.00Low
7/18/2022BTIG ResearchLower TargetBuy$45.00 ➝ $34.00Low
2/25/2022SVB LeerinkBoost TargetOutperform$40.00 ➝ $45.00Medium
12/21/2021Truist FinancialLower TargetBuy$55.00 ➝ $52.00High
8/5/2021SVB LeerinkLower TargetOutperform$67.00 ➝ $62.00High
6/30/2021OppenheimerReiterated RatingHoldHigh
5/6/2021HC WainwrightBoost TargetBuy$60.00 ➝ $65.00High
2/25/2021HC WainwrightBoost TargetBuy$44.00 ➝ $60.00Medium
2/25/2021SVB LeerinkBoost TargetOutperform$50.00 ➝ $60.00Medium
2/22/2021BTIG ResearchBoost Target$45.00 ➝ $56.00High
2/16/2021Truist FinancialBoost Target$40.00 ➝ $60.00Low
1/25/2021BTIG ResearchBoost TargetPositive ➝ Buy$37.00 ➝ $45.00High
1/19/2021LADENBURG THALM/SH SHBoost TargetBuy$27.50 ➝ $44.00Low
1/12/2021HC WainwrightBoost TargetBuy$26.00 ➝ $44.00High
1/11/2021OppenheimerDowngradeOutperform ➝ Market PerformHigh
1/5/2021BTIG ResearchBoost TargetBuy$30.00 ➝ $37.00N/A
12/17/2020StephensInitiated CoverageOverweight$31.00Low
10/19/2020BTIG ResearchBoost TargetBuy$23.00 ➝ $30.00High
10/15/2020HC WainwrightBoost TargetBuy$22.00 ➝ $26.00Low
10/12/2020SVB LeerinkBoost TargetOutperform$20.00 ➝ $30.00Medium
10/5/2020OppenheimerReiterated RatingBuy$32.00Medium
9/23/2020BTIG ResearchBoost TargetBuy$21.00 ➝ $23.00Medium
9/21/2020OppenheimerReiterated RatingBuy$32.00High
9/17/2020Truist FinancialInitiated CoverageBuy$24.00 ➝ $24.00Low
9/9/2020BTIG ResearchReiterated RatingBuy$21.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$22.00High
8/5/2020Needham & Company LLCInitiated CoverageHoldHigh
8/5/2020OppenheimerReiterated RatingBuyMedium
7/9/2020BTIG ResearchReiterated RatingBuy$21.00Low
7/9/2020Needham & Company LLCReiterated RatingHoldLow
5/6/2020HC WainwrightReiterated RatingBuy$22.00Low
5/6/2020LADENBURG THALM/SH SHBoost TargetBuy$20.00 ➝ $22.00High
5/5/2020BTIG ResearchReiterated RatingBuy$21.00Low
5/5/2020Needham & Company LLCInitiated CoverageHoldLow
5/5/2020OppenheimerReiterated RatingBuy$32.00Low
4/3/2020BTIG ResearchLower TargetBuy$24.00 ➝ $21.00Medium
4/2/2020Needham & Company LLCReiterated RatingHoldLow
2/26/2020BTIG ResearchReiterated RatingBuy$24.00High
2/26/2020HC WainwrightReiterated RatingBuyHigh
2/3/2020HC WainwrightBoost TargetBuy$21.00 ➝ $22.00High
11/5/2019Needham & Company LLCReiterated RatingHoldHigh
10/9/2019HC WainwrightInitiated CoverageBuy$19.00Medium
8/12/2019BTIG ResearchSet TargetBuy$24.00High
5/8/2019OppenheimerBoost TargetOutperform$23.00 ➝ $32.00Low
2/28/2019Needham & Company LLCDowngradeBuy ➝ Hold$17.92Medium
1/29/2019OppenheimerInitiated CoverageOutperform$23.00Low
11/6/2018Needham & Company LLCBoost TargetBuy$18.00Medium
11/6/2018BTIG ResearchBoost TargetBuy$17.00 ➝ $20.00Medium
8/8/2018Needham & Company LLCLower TargetBuy$15.00 ➝ $14.00Low
8/7/2018BTIG ResearchReiterated RatingBuy$17.00High
7/16/2018LADENBURG THALM/SH SHUpgradeNeutral ➝ BuyLow
5/9/2018BTIG ResearchReiterated RatingBuy$17.00Low
4/4/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$15.00High
3/6/2018Needham & Company LLCBoost TargetBuy ➝ Buy$5.00 ➝ $15.00High
3/6/2018LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
3/5/2018BTIG ResearchReiterated RatingBuy ➝ Buy$8.00 ➝ $13.00High
3/5/2018Piper Jaffray CompaniesBoost TargetOverweight$14.00High
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/31/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Vericel logo
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $28.53
Low: $27.72
High: $28.89

50 Day Range

MA: $24.95
Low: $21.09
High: $29.54

52 Week Range

Now: $28.53
Low: $17.30
High: $43.97

Volume

212,581 shs

Average Volume

447,149 shs

Market Capitalization

$1.35 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Vericel?

The following Wall Street analysts have issued research reports on Vericel in the last year: BTIG Research, HC Wainwright, Stephens, StockNews.com, SVB Leerink LLC, TheStreet, and Truist Financial Co..
View the latest analyst ratings for VCEL.

What is the current price target for Vericel?

5 Wall Street analysts have set twelve-month price targets for Vericel in the last year. Their average twelve-month price target is $36.20, suggesting a possible upside of 26.9%. SVB Leerink LLC has the highest price target set, predicting VCEL will reach $45.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $25.00 for Vericel in the next year.
View the latest price targets for VCEL.

What is the current consensus analyst rating for Vericel?

Vericel currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VCEL will outperform the market and that investors should add to their positions of Vericel.
View the latest ratings for VCEL.

What other companies compete with Vericel?

Other companies that are similar to Vericel include Adaptive Biotechnologies, Replimune Group, Iovance Biotherapeutics, Arcellx and Inhibrx. Learn More about companies similar to Vericel.

How do I contact Vericel's investor relations team?

Vericel's physical mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company's listed phone number is (617) 588-5555 and its investor relations email address is [email protected] The official website for Vericel is www.vcel.com. Learn More about contacing Vericel investor relations.